Hormone peptide tyrosine-tyrosine (PYY) is secreted into circulation from the gut L-endocrine cells in response to food intake, thus inducing satiation during interaction with its preferred receptor, Y 2 R. Clinical applications of systemically administered PYY for the purpose of reducing body weight were compromised as a result of the common side effect of visceral sickness. We describe here a novel approach of elevating PYY in saliva in mice, which, although reliably inducing strong anorexic responses, does not cause aversive reactions. The augmentation of salivary PYY activated forebrain areas known to mediate feeding, hunger, and satiation while minimally affecting brainstem chemoreceptor zones triggering nausea. By comparing neuronal pathways activated by systemic versus salivary PYY, we identified a metabolic circuit associated with Y 2 R-positive cells in the oral cavity and extending through brainstem nuclei into hypothalamic satiety centers. The discovery of this alternative circuit that regulates ingestive behavior without inducing taste aversion may open the possibility of a therapeutic application of PYY for the treatment of obesity via direct oral application.
Introduction
Two potent mechanisms that inhibit ingestive behavior are the induction of satiation and the negative modulation of palatability caused by taste aversion (TA) (Yamamoto, 2008) . Several gastrointestinal peptides, acting as endocrine modulators of ingestive behavior, have been shown inducing both effects. The list of such peptides includes glucagon-like peptide-1 (GLP-1; Thiele et al., 1997) , Exendin-4 (Kolterman et al., 2003) , cholecystokinin (Deutsch and Hardy, 1977) , and peptide tyrosine-tyrosine (PYY) (Halatchev and Cone, 2005) .
PYY, a molecular mediator of satiation, is released predominantly from enteroendocrine L-cells of the distal intestine in response to food intake (FI). PYY exists in two forms, PYY 1-36 and PYY . The former is active on all Y receptors and is converted to PYY 3-36 during cleavage by dipeptidase IV. PYY 3-36 retains high affinity only for the Y 2 receptor (Y 2 R) (Blomqvist and Herzog, 1997) and acts by reducing FI and adiposity. Although PYY 3-36 systemic administration inhibits FI in rodents, monkeys, and humans (Batterham et al., 2002; Chelikani et al., 2005; Degen et al., 2005; Moran et al., 2005; Talsania et al., 2005) , the exact mechanism by which it controls ingestive behavior has not been fully elucidated.
Evidence suggest that circulating PYY 3-36 crosses the bloodbrain barrier (Nonaka et al., 2003) and interacts with Y 2 Rs expressed in specific brain areas (Fetissov et al., 2004; Stanić et al., 2006) . Conversely, there is evidence demonstrating that circulating PYY 3-36 also inhibits FI through interaction with Y 2 Rs expressed in abdominal sensory branches of the vagus nerve . However, its role is not entirely clear because vagal denervation only blocks the anorexic response to peripheral administration of PYY 3-36 in rats but not in mice (Halatchev and Cone, 2005) .
Adding more complexity to the physiological role of PYY 3-36 , we documented recently that PYY 3-36 is also present in saliva (Acosta et al., 2011) . Although its innate physiological functions have yet to be determined, we have shown that salivary PYY can modulate FI and body weight (BW) accumulation. The anorexigenic effect is likely mediated through the activation of Y 2 Rpositive (Y 2 R ϩ ) cells in the oral mucosa. These data led us to hypothesize that a putative neuronal circuit, initiated in the oral cavity, extends through the brainstem to hypothalamic areas, via cranial nerve afferents. If such a pathway exists, it would have to relay the information through the brainstem. Incidentally, neurons in the area postrema (AP) of the brainstem are known to partially mediate TA in response to the PYY 3-36 administered peripherally (Halatchev and Cone, 2005) or by intranasal spray (Gantz et al., 2007) .
The purpose of the current investigation was to investigate the mechanism by which salivary PYY 3-36 inhibits ingestive behavior.
First, we tested whether the reduction in FI after salivary PYY augmentation was related to aversive behavioral responses. Moreover, by comparing neuronal pathways engaged by systemic versus salivary PYY 3-36 , we aimed to identify neurons in the AP, nucleus of the solitary tract (NST), parabrachial nucleus (PBN), and hypothalamic areas that are activated in response to the orally applied PYY 3-36 .
Materials and Methods

Animals
Male wild-type C57BL/6 and PYY knock-out (KO) mice (PYY Ϫ/Ϫ ) (Boey et al., 2006) weighing 20 -25 g were housed individually in hanging wiremesh cages in a room with 12 h light/dark cycle. Animals were provided ad libitum access to regular mice chow and water except as otherwise noted below (see Experimental procedures). The Institutional Animal Care and Use Committee of the University of Florida approved all experimental procedures.
Test substances
The TA experiment was performed using PYY 3-36 from Bachem and LiCl from Alfa Aesar. For the intraperitoneal injections, the solution was injected into the peritoneal cavity at a dose of 6 g/100 g BW. For the oral spay treatment, PYY was diluted at the concentrations of 0.075, 0.15, or 0.225 mg/ml. The solutions were administered into the oral cavity at the doses of 6, 12, or 18 g/100 g BW. LiCl was dissolved in sterile distilled water to a final concentration of 0.15 M; mice were injected intraperitoneally with a volume equivalent to 2% of their BW. For the conditioned TA (CTA) experiment with liquid, flavored solutions were made of diluted Kool-Aid (either 0.15% saccharine with 0.05% cherry Kool-Aid or 0.15% saccharine with 0.05% grape Kool-Aid). For the CTA with solid food, we used flavored apple and orange Crunchies (BetterPets).
Experimental procedures Treatment with orally administered substances
With the exception of 125 I-PYY, the oral treatment described herein refers to the substances administered by an oral spray (OS) targeting receptors in the oral cavity. The solutions were administrated into the oral cavity in a single puff, as described previously (Acosta et al., 2011) , using a sterile 9 ⁄16-inch dram (8 ϫ 58 mm) glass sampler bottle (each puff delivers ϳ30 l of solution to the oral cavity in a harmless manner).
In vivo treatment of mice with PYY KO mice were deeply anesthetized, and 125 I-labeled human PYY 1-36 (Phoenix Pharmaceuticals) was administered into the oral cavity by micropipette at the dose of 7 Ci/100 g BW (equivalent to 18 g/100 g BW) in a total volume of 155 l, or intraperitoneally injected 4-(6, 11-dihydro-6-oxo-5H-dibenz[b,e] azepin-11-yl)-1-piperazinyl]-2-oxoethyl]-cyclopentaneacetamide antagonist was applied at 50 M excess as described previously (Acosta et al., 2011) . Five minutes after oral administration, mice were killed; tongue tissues were harvested and extensively washed in several changes of PBS until no above-the-background radioactivity was detected by Geiger counter. After systemic administration, the animal was killed 15 min after injection, and the tongue was treated as described above. Sagittal sections of the fresh-frozen tongue tissues were exposed to a one-sided x-ray film (Kodak BioMax MR) for 3 d at Ϫ20°C. After exposure, sections were stained with hematoxylin (Merck) and eosin (Sigma) (H&E). To investigate histological localization of 125 I-labeled human PYY 1-36 within the tongue epithelium, the slides were examined by polarized light microscopy.
Conditioning procedure preceding immunohistochemistry
To test whether salivary PYY augmentation activates neurons in the brainstem and hypothalamic nuclei, groups of mice were conditioned for repeated cycles of fasting for 24 h, followed by refeeding. A treatment combination of intraperitoneal injections and OS administration was incorporated into the conditioning protocol so that all mice in all control and experimental groups were subjected to the same combination of OS/intraperitoneal injections. Mice in control fasted groups were fasted over the duration of the experiment. All mice were killed at 1 h after the treatment. Brains were harvested and neuronal activity was evaluated by probing the induction of c-fos, phosphorylated extracellular signalregulated kinase ( p-ERK ) expression, or other neuronal markers as described below.
c-Fos immunohistochemistry
All mice were subjected to the conditioning procedure described above. LiCl was used as a positive control treatment. PYY 3-36 injected intraperitoneally was used as another positive control characterized previously to induce CTA (Halatchev and Cone, 2005; Chelikani et al., 2006) . Five groups of mice (n ϭ 4 each) were fasted for 24 h: (1) negative control (see Fig. 3 , group "Fast"); (2) positive control, fed for 1 h and killed 1 h later (see Fig. 3 , group "Fed"); (3) positive CTA group, injected with LiCl and killed 1 h later; (4) positive CTA group, administered PYY 3-36 intraperitoneally (6 g/100 g BW; see Fig. 3 , group "PYY i.p.") and killed 1 h after the treatment; and (5) experimental group, administered PYY 3-36 OS (6 g/100 g BW; see Fig. 3 , group "PYY OS") and killed 1 h after the treatment.
To collect brains, a previously described protocol was followed (Gorbatyuk et al., 2001) . Briefly, mice were deeply anesthetized with sodium pentobarbital and perfused sequentially through the ascending aorta with the following: (1) 20 ml of heparinized saline; and (2) 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (PB). The brains were postfixed in the same fixative for 4 h and then immersed in 30% sucrose in 0.1 M PB at 4°C. A series of 40-m-thick coronal sections were cut through the rostrocaudal extent on a cryostat (Leica CM3050 S) and collected in anti-freezing storage solution.
For the bright-field photomicrographs, sections were preincubated first with 0.5% H 2 O 2 -10% methanol for 15 min and then with 5% normal goat serum for 1 h. Sections were incubated for 36 h at 4°C with anti-c-Fos primary antibody (1:2000; Santa Cruz Biotechnology). Incubation with secondary goat anti-rabbit biotinylated antibody (1:400, for 4 h) was followed by incubation with avidin-biotin-peroxidase complex (ABC; Vector Laboratories). Reactions were visualized using 3,3-diaminobenzidine as a chromagen. c-Fos ϩ cells on the representative microphotographs were counted by operators blind to identity of the group.
p-ERK and vasopressin double immunofluorescence
Sections from fasted, PYY 3-36 intraperitoneally, and PYY 3-36 OS-treated mice were double stained with anti-phospho-p44/42 MAP kinase ( p-ERK) (Cell Signaling Technology) and vasopressin [anti-arginine-vasopressin (AVP) antibody; Millipore Bioscience Research Reagents]. Brains were collected and postfixed as described above. Series of 25-m-thick coronal sections were cut through the rostrocaudal extent and mounted onto Fisher Superfrost Plus slides. p-ERK immunolocalization was conducted using the tyramide signaling amplification (TSA) kit (PerkinElmer Life and Analytical Sciences), whereas vasopressin was detected through the standard protocol. Tissues were blocked in 0.3% H 2 O 2 in Tris-buffered saline for 30 min at room temperature (RT) to eliminate endogenous peroxidase activity, followed by blocking with 10% donkey serum in TNT (0.1 M Tris HCl, pH 7.5, 0.15 M NaCl, and 0.05% Tween 20) for 60 min at RT to reduce nonspecific antibody binding. Sections were then incubated simultaneously with the two primary antibodies: rabbit anti-p-ERK (1:2000) and guinea pig antivasopressin (1:1000) in TNT for 72 h at 4°C. Tissues were subsequently incubated with secondary goat anti-rabbit IgG (FabЈ)2 conjugated to horseradish peroxidase (1:1000 for 60 min at RT; Abcam), followed by incubation with fluorescein provided in the TSA kit (1:300, for 7 min at RT; PerkinElmer Life and Analytical Sciences) to detect p-ERK. To detect vasopressin, the slides were subsequently incubated with Cy5 donkey anti-guinea pig IgG (1:100 in TNT for 60 min at RT; Jackson ImmunoResearch).
p-ERK and ␣-melanocyte-stimulating hormone doubleimmunofluorescence
Sections from fasted, PYY 3-36 intraperitoneally, and PYY 3-36 OS-treated mice were double stained with anti-p-ERK and anti-␣-melanocyte-stimulating hormone (␣-MSH) (Millipore Bioscience Research Reagents). The protocol was identical to the one described above; anti-␣-MSH was used at a 1:2000 concentration. To detect ␣-MSH, the slides were incubated with Alexa Fluor 555 donkey anti-sheep IgG (1:1000; Invitrogen).
c-Fos and tyrosine hydroxylase double immunohistochemistry
Sections from fasted, PYY 3-36 intraperitoneally, and PYY 3-36 OS-treated mice were double stained with anti-c-Fos (1:1000; Millipore) and antityrosine hydroxylase (TH) antibody (1:500; Cell Signaling Technology).
c-Fos and GLP-1 double immunohistochemistry
Sections from fasted, PYY 3-36 intraperitoneally, and PYY 3-36 OS-treated mice were double stained with anti-c-Fos (1:1000; Santa Cruz Biotechnology) and anti-GLP-1 antibody (1:1000; Peninsula Lab).
c-Fos and oxytocin double immunohistochemistry
Sections from fasted, PYY 3-36 intraperitoneally, and PYY 3-36 OS-treated mice were double stained with anti-c-Fos (1:1000; Santa Cruz Technology) and anti-oxytocin (OXT; 1:1000; Abcam).
CTA behavioral studies
Both oral (OS) and systemic (intraperitoneally) PYY 3-36 were administered at identical matching doses (6 g/100 g BW) because it had been shown to reliably and reproducibly inhibit FI by either OS (Acosta et al., 2011) or intraperitoneally (Halatchev and Cone, 2005) . Two complementing paradigms were used to study the induction of CTA by PYY 3-36 : (1) one with liquid and (2) one with solid food. Both protocols were performed as described previously (Halatchev and Cone, 2005; Chelikani et al., 2006) . Mice were habituated to individual housing 2 weeks before the experiments. All subsequent procedures were conducted in the animal's home cages from 7:00 P.M. and 9:00 P.M. (dark period from 7:00 P.M. to 7:00 A.M.). Animals had ad libitum access to regular rodent chow at all times. Water was withdrawn 23 h before the start of the first day of training. Mice had access to water or the flavored solutions every day for 1 h.
Liquid paradigm
Habituation procedure. To habituate to timing of liquid presentation, mice were conditioned to consume water during a 5 d training period (Table 1 , open cells). After 23 h of liquid deprivation, water was offered for 1 h (7:00 P.M. to 8:00 P.M.) in two different bottles that were situated equidistant from the food hopper. The amount consumed was determined by weighing the bottles before and after each training session. To habituate mice to intraperitoneal injections and the OS, after each training session, animals were injected intraperitoneally with a volume of sterile isotonic saline solution (SS) equal to 2% of BW, and, at the same time, water was administered to the oral cavity via an OS.
Conditioning procedure. Immediately after training, animals were subjected to a 12 d conditioning procedure consisting of the following three 4 d sequences (Table 1 ). The animals were assigned at random to either of two flavor conditions and were subjected to a regimen of OS and intraperitoneal injections. During the same 1 h period (7:00 P.M. to 8:00 P.M.) on day 1, mice were offered a novel flavored liquid in both bottles (that could be either grape or cherry Kool-Aid prepared as described previously; Chelikani et al., 2005) , followed by one of the following treatment regimens: (1) PYY 3-36 OS at doses indicated, accompanied by an intraperitoneal injection of SS; (2) water OS and PYY 3-36 intraperitoneally; (3) water OS and LiCl intraperitoneally; or (4) water OS and SS solution intraperitoneally. On day 2, all the mice received water for 1 h to allow for recovery from the treatment regimen. On day 3, each mouse received the alternative novel flavor (i.e., if an animal received grape during the first day, it received cherry in the third and vice versa), and after 1 h, all mice received an SS injection intraperitoneally and water OS. On day 4, they again received water during the 1 h period. This 4 d sequence was repeated three times for a total of three conditioning trials over 12 consecutive days.
Preference trials. On 2 consecutive days immediately after the conditioning period, each mouse was given simultaneous access to the two flavored solutions, and the amount consumed of each stimulus was measured. For each mouse, the left-right position of the bottles containing the two flavored solutions was reversed during the second day. Water was presented as flavored solution in two separate bottles equidistant from the food. Treatment consisted of one of the following regimens: (1) PYY 3-36 OS at different doses and SS intraperitoneally; (2) water OS and PYY 3-36 intraperitoneally; (3) water OS and LiCl intraperitoneally; or (4) water OS and SS intraperitoneally.
Solid food paradigm (Table 1, shaded cells)
For the CTA experiment with solid food, procedures were the same as those described above, but flavored Crunchies were used instead flavored solutions. Mice were fasted for 23 h instead of being water deprived for 23 h.
Regular chow or flavored Crunchies were presented in two separate trays equidistant from water. Treatment consisted of one of the following regimens: (1) PYY 3-36 OS at different doses and SS intraperitoneally; (2) water OS and PYY 3-36 intraperitoneally; (3) water OS and LiCl intraperitoneally; or (4) water OS and SS intraperitoneally.
Statistics
Statistical analyses were performed using IBM SPSS Statistics version 17 software. Data are expressed as group means Ϯ SEM. For the TA experiments, significance across individual treatments was determined using one-way ANOVA with Dunnett's post hoc test when three or more groups were compared. Unpaired Student's (two-tailed) t test was used to determine the significance when two groups were compared. For c-Fos activation experiments, one-way ANOVA with Dunnett's test post hoc was used for comparing different treatments with the fasting control group, followed by one-way ANOVA with both Fisher's least significant difference and Tukey's post hoc tests to determine significance across individual treatments. Tukey's test was used to control type I error rate resulting from multiple pairwise comparisons. The statistical rejection criterion was set at p Յ 0.05.
Results
Salivary PYY 3-36 does not induce CTA PYY 3-36 administered systemically had been shown to reduce FI (Batterham et al., 2002) while at the same time inducing CTA (Halatchev and Cone, 2005) . The latter manifestation is apparently related to the activation of neurons in the AP brainstem area mediating, in part, aversive reactions (Halatchev and Cone, 2005) . To test whether anorexic doses of salivary PYY 3-36 induce CTA in a similar manner, we conducted the following behavioral study.
Inducing CTA with flavored liquid PYY 3-36 OS at doses that reliably and reproducibly inhibit FI (6 g/100 g BW) (Acosta et al., 2011) did not produce TA in mice, whereas PYY 3-36 administered intraperitoneally at the same dose did (Fig. 1A) . Negative controls that received saline intraperitoneally and water OS paired to both flavors did not show any preference for either of the flavors and drank equal amounts in response to both stimuli. Conversely, positive controls that were treated with LiCl showed a significant reduction of treatmentpaired flavor, with the difference of consumption between the two flavors reaching 75% (t (14) ϭ Ϫ6.6, p Ͻ 0.001). Mice that received PYY 3-36 intraperitoneally (6 g/100 g BW) drank 65% less of the PYY 3-36 intraperitoneally paired flavor versus the saline paired flavor (t (14) ϭ Ϫ5.1, p Ͻ 0.001). PYY 3-36 OS-treated mice drank equal amounts from the two flavors (t (14) ϭ 0.0, p ϭ 0.984).
Previously, we showed that higher doses of PYY 3-36 applied orally for 21 consecutive days results in a significant reduction of BW accumulation in mice (Acosta et al., 2011) . Therefore, to exclude the possibility of mounting CTA at higher doses, the above experiment was repeated using PYY 3-36 OS at 12 and 18 g/100 g BW. Likewise, neither of these doses resulted in preference or aversion for any of the flavors (Fig. 1B) , with the LiCl control group consistently showing a reduction of the paired flavor consumption (t (14) ϭ Ϫ16.5, p Ͻ 0.001).
Inducing CTA with flavored solid food To corroborate these data and to model a potential therapeutic application scenario, we repeated the behavioral experiment using flavored solid food. Importantly, using PYY 3-36 OS at 6 or 18 g/100 g BW treatment doses, we observed similar results to the one with the liquid paradigm (Fig. 1C) . PYY 3-36 OS paired flavors had no effect on the amount of food consumed, although there was a significant difference apparent for the PYY 3-36 intraperitoneally treated group (t (14) ϭ Ϫ1.4, p Ͻ 0.001) and even more so for the LiCl control group (t (14) ϭ Ϫ16.6, p Ͻ 0.001). Thus, the augmentation of salivary PYY 3-36 at a dose that reliably inhibits FI, or even at a threefold higher dose, does not induce CTA.
Salivary PYY 3-36 binds to lingual Y 2 R receptors
We have demonstrated that orally applied PYY 3-36 does not enter into circulation, whereas circulating PYY 3-36 efficiently transudates from plasma into saliva (Acosta et al., 2011) . Thus, the observed anorexic effect of salivary PYY 3-36 has to be related to the effector interacting locally with the cognate receptors expressed in the oral mucosa (Acosta et al., 2011; Hurtado et al., 2012) . To determine whether salivary PYY binds to Y 2 R expressed in lingual epithelia cells, we used 125 I-labeled PYY 1-36 administered into the oral cavity of PYY KO mice. These mice were used to exclude a possible competition of endogenous salivary PYY with the radiolabeled ligand. Five minutes after treatment, radiolabeled PYY was found to be bound to both dorsal and ventral tongue surface epithelia (Fig. 2 A, D) . When labeled PYY was mixed with the Y 2 R-specific antagonist BIIE0246 (Doods et al., 1999) , binding was abolished, thus not only providing additional support for the specificity of the interaction but also identifying the Y 2 R as the major interaction site (Fig. 2 B, E) . Moreover, when radiolabeled PYY was administered intraperitoneally, the lingual epithelial binding of 125 I-PYY was robust as soon as 15 min after injection (Fig. 2C,F ) , confirming our recent finding that systemic PYY is efficiently transported into saliva (Acosta et al., 2011) . H&E staining of the sections (Fig.  2 D, F ) showed no preference of the peptide distribution where- upon silver granules could be seen localizing in all layers, including superficial dorsal keratinocytes as well as in basal epithelial progenitor cells known to express Y 2 R (Hurtado et al., 2012) .
Effect of salivary PYY 3-36 on brainstem neurons
To investigate whether the postulated interaction of salivary PYY 3-36 and its cognate receptors induces afferent neuronal pathways, we studied the patterns of c-fos activation in the NST, AP, and PBN.
The data of the current report have to be interpreted with the following notions in mind. On one hand, we showed previously that PYY 3-36 administered peripherally is transported into the oral cavity from the bloodstream (Acosta et al., 2011) , a fact now supported by the direct experiment with 125 I-PYY (Fig. 2C ). Thus, in the PYY intraperitoneally injected positive controls used in this study, PYY 3-36 would activate hypothalamic neurons as characterized previously (Batterham et al., 2002; Halatchev and Cone, 2005) , and, during diffusion into the oral cavity, it will also affect a putative pathway that originates in the oral mucosa. Conversely, PYY 3-36 , applied by OS, does not leak retrogradely into the bloodstream (Acosta et al., 2011) . As a result, it would not affect neurons targeted by circulating PYY, while, nonetheless, activating oral Y 2 R cells and putative afferent pathways.
The NST has two major functional divisions: (1) an anteriorlateral oral-gustatory half [hereafter referred to as "rostral" NST (rNST)]; and (2) a posterior-medial visceral afferent half ["caudal" NST (cNST)] (Hamilton and Norgren, 1984; Travers and Norgren, 1995) . In the AP, known to mediate aversive response, the different activation patterns induced by salivary versus systemic PYY would also help to explain the lack of CTA after OS PYY application. Therefore, three areas were analyzed separately: (1) the rNST; (2) the cNST; and (3) the AP (Fig. 3A , shaded areas unilaterally shown on the right aspect of the solitary tract). For this experiment, both the OS and intraperitoneal groups were treated with the identical doses of PYY 3-36 (6 g/100 g BW) that were identified previously to reliably reduce FI (Batterham et al., 2002; Acosta et al., 2011 ). An additional group of control mice were injected intraperitoneally with LiCl to induce visceral malaise.
rNST
In the rostral subdivision, all subnuclei (medial, rostrocentral, rostrolateral, and ventral; Corson et al., 2012) showed similar response trends; therefore, we combined c-Fos ϩ neurons in these areas during tabulation (Fig. 3B , the respective shaded area, D, dashed oval in the brain sections). Neuronal activation differed significantly across the five groups (F (4,121) ϭ 60.9, p Ͻ 0.001). Tukey's post hoc comparisons of these five groups indicate that PYY OS-treated groups showed a significant reduction in the numbers of c-Fos ϩ neurons compared with both fasting (p ϭ 0.001) and PYY intraperitoneally (p ϭ 0.025; Fig. 3C ) groups. Animals in the fed group responded by activating neurons, whereas there was no significant effect in the rNST neurons in the LiCl-treated group (p ϭ 0.865).
cNST
The cNST is known to relay satiation signals from the alimentary tract to the hypothalamus (Hamilton and Norgren, 1984) . In the caudal aspect, we studied the NST at the level of the AP (Fig. 3A , shaded area). Within this region, we tabulated c-Fos ϩ neurons within the medial NST (mNST; Fig. 3E , outlined area) in which we found only few c-Fos ϩ cells in fasted animals. Neuronal activation differed significantly across groups (F (4,251) ϭ 129, p Ͻ 0.001). However, Tukey's post hoc comparison of these groups showed that, unlike the rostral part, the cNST responded to LiCl treatment in a very robust manner compared with fasted mice (p Ͻ 0.01). In addition, both fed and PYY 3-36 intraperitoneal control groups showed significant increases in c-fos expression compared with fasted mice as well (p Ͻ 0.01 in both cases), whereas there was no response in the OS group (p ϭ 0.187; Fig. 3F ).
AP
In the AP, all four groups showed a significant activation of c-Fos in neurons when pairwise compared with the fasted group (Fig.  3 E , G; F (4,192) ϭ 36.7, p Ͻ 0.001). Similar to the cNST area, the PYY 3-36 OS-treated group showed the least neuronal activation ( p ϭ 0.026), and this was significantly less than in the PYY 3-36 intraperitoneally treated group ( p ϭ 0.003) but not different from the fed group ( p ϭ 0.501).
Overall, neurons in both the rostral and caudal brainstem clearly responded in distinctive ways to the PYY treatment depending on the administration route. For example, rostral neurons in the OS group showed a significantly lower degree of activation compared with the intraperitoneal group. At the same time, caudal mNST neurons were either not activated in the OS group or showed a significantly lower degree of activation in the AP. Such a differential pattern could reflect the distinctive mechanisms of PYY 3-36 action: humoral via circumventricular organs when administered systemically versus neuronal if applied by OS.
PBN
The PBN is a major relay for gustatory and visceral information and mediates anorexia associated with malaise induced by intraperitoneal injection of LiCl (Rinaman and Dzmura, 2007 Reilly, 2002). Direct injections of cannabinoid or -opioid receptor agonists into the PBN stimulate feeding (DiPatrizio and Simansky, 2008) . Thus, the PBN can process both aversive and appetitive ascending visceral information to modulate feeding behavior.
The PBN consists of nine cytoarchitectonically and functionally different subnuclei (Fulwiler and Saper, 1984; Hashimoto et al., 2009) . For the purpose of quantifying the effect of the treatment, we combined several subnuclei into medial (mPBN) and lateral (lPBN) subdivisions. This was attributable to the fact that the PBN nuclei are physically divided into medial and lateral subdivisions by fibers of the superior cerebellar peduncle, and, in some cases, it was difficult to delineate the cytoarchitectonic boundaries for these particular subdivisions of subnuclei. The segregation of taste and visceral projections to the PBN is not as clear as in the NST (Hermann et al., 1983) . Nevertheless, visceral afferent projections arising from the cNST terminate primarily in nuclei of the lPBN, whereas taste-responsive neurons are found predominantly in the mPBN (Karimnamazi and Travers, 1998) . lPBN During fasting, a well defined group of c-Fos ϩ neurons can be identified in the area (Fig. 4A) corresponding to the lateral external PBN (lePBN). It is established that neurons in these subnuclei receive projections from AP (Cunningham et al., 1994) and send projections to the lateral hypothalamic area (LHA) and the amygdala (Amy) (Tokita et al., 2010) . In fed mice, as well as PYY intraperitoneally, the number of c-Fos ϩ neurons in lePBN was significantly reduced ( p ϭ 0.006 and p ϭ 0.025, respectively), whereas in PYY OS group, there was no significant change (Fig. 4 A, B ; p ϭ 0.884). mPBN During fasting, there were few c-Fos ϩ neurons in the mPBN, but their number increased approximately twofold after feeding ( p ϭ 0.009). Treatment with PYY, both intraperitoneally and OS, reduced the number of c-Fos-activated neurons compared with both fed and fasted mice, albeit not significantly so when compared with the latter group (Fig. 4 A, C ; p ϭ 0.086 and p ϭ 0.114, respectively).
Effects of systemic and salivary PYY 3-36 on the expression of c-Fos in catecholaminergic neurons in the NST and AP
To characterize the chemical nature of the PYY-activated neurons, we used TH as a catecholaminergic neuronal marker. In the AP, as well as in the mNST, there were few if any TH-immunoreactive (IR) neurons that were c-Fos ϩ , and neither intraperitoneal nor OS PYY 3-36 treatment had any effect (Fig. 3H ) . However, both types of PYY treatment induced c-Fos in a subpopulation of TH-IR large neurons localized at the mNST ventral-lateral edge at the level of and rostral to the AP level (7.56 -7.2 mm caudal of bregma; Paxinos and Franklin, 2001; Fig. 5 F, I ). NST TH ϩ neurons contribute into a major ascending pathway through which vagal sensory information reaches the hypothalamus. These neurons play a key role in the integration of visceral satiety signals and may be involved in mediating brainstem satiation circuits to the hypothalamus. However, the majority of the activated c-Fos ϩ neurons were shown to be noncatecholaminergic, a finding consistent with previously published observations (Blevins et al., 2008) .
Effect of PYY 3-36 treatment on the expression of c-Fos in GLP-1 neurons in the mNST
GLP-1 neurons process pre-pro-glucagon into GLP-1, GLP-2, oxyntomodulin, and glicentin. These neurons are subject to leptin signaling (Vrang et al., 2008) and project mainly to the hypothalamic nuclei involved in appetite regulation: paraventricular nucleus (PVN), dorsomedial hypothalamus (Vrang et al., 2007) , and arcuate nucleus (Arc; Llewellyn-Smith et al., 2011) . To establish the possible involvement of GLP-1-signaling in response to PYY 3-36 treatment, we conducted double immunohistochemistry for GLP-1 and c-Fos in mNST neurons localized ventrally of the caudal aspect of the AP. Both intraperitoneal and OS PYY 3-36 treatment induced c-Fos in a subpopulation of GLP-1-IR neurons (Fig. 5J ).
Salivary PYY 3-36 activates hypothalamic c-Fos
The mechanism of the anorexigenic action of peripherally applied PYY 3-36 could be related to its action on hypothalamic neurons (Batterham et al., 2002) . Alternatively, peripheral PYY 3-36 may inhibit FI by signaling through Y 2 R expressed in the vagus nerve . Both pathways have been shown to activate neurons in the hypothalamus. To test whether salivary PYY augmentation activates hypothalamic centers, four groups of mice were conditioned as described in Materials and Methods. There were few c-Fos ϩ cells in fasted animals in Arc, PVN, and LHA and their numbers were markedly induced in all areas after feeding (Fig. 6 ). All these activated areas are known to mediate both satiety and hunger. Data in this report are consistent with previously published findings describing activation of neurons in hypothalamic areas in anticipatory response to feeding in habituated animals (Johnstone et al., 2006) . Similar to the mice from the fed control group, orally treated and intraperitoneally injected PYY 3-36 groups showed activation of neurons in Arc (Fig. 6 , top row; F (3, 20) ϭ 33.8, p ϭ 0.02), PVN (Fig. 6 , middle row; F (3,12) ϭ 10.1, p ϭ 0.001), and LHA (Fig. 6 , bottom row; F (3,21) ϭ 25.6, p Ͻ 0.001). Although PYY 3-36 intraperitoneally injected mice displayed an increase in a number of c-Fos ϩ PVN neurons, this did not reach statistical significance after running Tukey's post hoc analysis ( p ϭ 0.13).
Salivary PYY 3-36 activates hypothalamic p-ERK1/2
Another morphological marker of the neuronal activation is ERK1/2, also known as p44/42 mitogen-activated protein kinase (Xu et al., 2002; Belgardt and Brüning, 2010). After phosphorylation, activated p-ERK1/2 can initiate additional downstream signaling, in particular, an increase in c-Fos biosynthesis, including the upregulation of its gene transcription and protein phosphorylationmediated stabilization (Gorbatyuk et al., 2001; Glauser and Schlegel, 2007; Aoyagi et al., 2009) . There is also an association of p-ERK1/2 signaling and the expression of pro-opiomelanocortin (POMC), the precursor of ␣-MSH (Jenks, 2009; Kuribara et al., 2011) , a strong anorexic central mediator of FI and increased metabolic activity (Morton et al., 2006) . To validate c-Fos-related data and to establish the morphological identity of the activated neurons, we conducted a double immunostaining with p-ERK1/2 and ␣-MSH in the Arc or AVP in the PVN. For this experiment, brain sections from fasted, PYY 3-36 intraperitoneally, and PYY 3-36 OS-treated mice were analyzed. The pattern of p-ERK1/2 activation followed the same trend as the pattern of c-Fos expression in the Arc and PVN: p-ERK expression level was higher in PYY 3-36 intraperitoneally and PYY 3-36 OS-treated mice compared with fasted mice (Fig. 7C ,G,K in the Arc; Fig. 8C ,G,K in the PVN). A majority of ␣-MSH ϩ cells were also p-ERK1/2 ϩ (Fig. 7 H, L , open arrowheads), indicative of their involvement in anorexigenic pathways. In the PVN, both intraperitoneal and OS PYY 3-36 treatments activated AVP ϩ neurons (Fig. 8 H, L, open arrowheads) .
Salivary PYY 3-36 does not activate OXT neurons in the PVN
To further characterize the identity of the activated neurons, we costained the PVN sections with OXT and c-Fos antibodies (Fig.  9) . Although OXT ϩ neurons were abundantly observed in the area of c-Fos activation, there was very little if any colocalization. Considering the distinct profile of OXT and AVP expression in the parvocellular PVN, this almost certainly indicates that the area of c-Fos/ERK activation was that of the medial parvocellular division of the PVN almost exclusively containing corticotropin-releasing factor hormone (CRF) neurons (Gorbatyuk et al., 2001) .
Discussion
Anorexic peptide PYY 3-36, administered at supraphysiological doses induces CTA in nonemetic species. In humans, this aversive reaction is associated with visceral illness and nausea (Degen et al., 2005) . The current study describes an alternative route of PYY 3-36 administration that reliably induces an anorectic response without inducing CTA. Furthermore, our data support the existence of the previously postulated putative anorexic pathway activated by salivary PYY 3-36 (Acosta et al., 2011) and acting through the cognate YRs expressed in oral mucosa (Hurtado et al., 2012) .
Because systemic PYY 3-36 had been implicated in mounting CTA by activating AP neurons (Halatchev and Cone, 2005; Chelikani et al., 2006) , it was of interest to test whether orally administered PYY 3-36 induced aversive responses as well. Although PYY 3-36 intraperitoneally injected mice indeed developed CTA to an associated flavor, no such response was documented in mice treated with OS PYY , even at the highest dose of 18 g/100 g BW.
Neuronal pathways in the brainstem
The NST consists of two major divisions, rostral and caudal, mediating and integrating gustatory and visceral information, respectively. rNST mediates gustatory perception via terminal fields of the V, VII cranial nerves from anterior 2/3 of the tongue and the palate (Contreras et al., 1982) and the projections of the lingual-tonsilar branch of the IX (Hamilton and Norgren, 1984) . Conversely, cNST and AP receive projections of vagal afferent fibers that innervate different visceral organs (Kalia and Sullivan, 1982; Katz and Karten, 1983; Belecky and Smith, 1990; Travers and Nicklas, 1990 ). This partition is further manifested in distinctive afferent projections to the higher brains areas (Fig. 10) .
The PYY 3-36 intraperitoneal group showed significant reduction of c-Fos ϩ neurons in the rNST compared with fasting and feeding conditions. In the OS-treated group, the neuronal inhibition was even more pronounced. These data are consistent with the recent report showing that the inhibition of the opioid/ GABAergic neurons in the rNST could suppress ingestive behavior (Kinzeler and Travers, 2011). The reduction in the numbers of activated neurons in the rNST could result from inhibiting descending projections from the gustatory cortex (Smith and Li, 2000) , the lateral hypothalamus (Cho et al., 2002) , and the Amy (Lundy and Norgren, 2001 ), all modulating gustatory activity within the NST and/or PBN. In general, descending influences from the forebrain are excitatory, although there is some evidence for inhibitory effects as well (Hayama et al., 1985; Di Lorenzo and Monroe, 1995; Smith and Li, 2000; Lundy and Norgren, 2001) . Recent evidence has shown that, in rats, a major descending projection from the Amy to the NST is GABAergic (Saha et al., 2000) . Together, this evidence suggests that the responses of gustatory neurons in the brainstem are subject to descending forebrain modulation, most likely reflecting the animal's physiological state or previous experience.
The neurons in the AP and cNST showed similar responses to the systemic and oral PYY administration. Both cNST and AP groups responded by significantly increasing the numbers of c-Fos-IR cells compared with the fasted but not the fed group. Both nuclei responded to LiCl in a very dramatic way, consistent with the view that the AP projects into the cNST (Date et al., 2006) and that it is a chemoreceptor trigger zone mediating nausea (Bernstein et al., 1992) . However, the OS treatment induced significantly fewer neurons in the AP compared with systemic treatment, consistent with the absence of the CTA response.
It is conceivable that these c-Fos-IR neurons are pre-proglucagon neurons that are known to be localized in the cNST. A significant body of evidence supports a role of the NST pre-proglucagon neurons as mediators of the anorexia elicited by visceral malaise. Rinaman (1999a) has shown that three potent interoceptive stressors (CCK, LiCl, and LPS) induce c-Fos expression in a large proportion of GLP-1-IR neurons in the NST, and LiClinduced suppression of FI can be partially blocked by previous central administration of GLP-1 receptor antagonists (Rinaman, 1999b; Seeley et al., 2000) , pointing to a functional role of central GLP-1 neurons in LiCl-induced anorexia. Moderate gastric distension can activate hindbrain GLP-1/2-containing neurons, consistent with a role of central pre-pro-glucagon-derived peptides as FI inhibitors. Therefore, these data support the view that the medullary GLP system is involved in appetite control and is activated by stimuli within the behavioral continuum ranging from satiety to nausea (Vrang et al., 2003) .
Notably, the changes in the numbers of c-Fos-IR neurons in mPBN reflected changes in rNST: compared with fasted mice, their numbers increased after feeding and were reduced by PYY 3-36 treatment. This effect could be explained by the fact that the afferent projections from taste-responsive neurons arising from the rNST terminate primarily in the mPBN (Karimnamazi and Travers, 1998) and that the activation/suppression of rNST neurons directly affect mPBN neurons.
Neuronal pathways in the hypothalamus
Administration of an anorexigenic dose of PYY 3-36 , whether it is intraperitoneally or by an OS, increased the number of c-Fos ϩ neurons in the forebrain Arc, PVN, and LHA nuclei and increased p-ERK in the Arc and PVN nuclei. Therefore, the inevitable conclusion is that supraphysiological salivary PYY 3-36 can modulate satiety/feeding centers without reaching plasma. Phenotypic identification neurons in the PVN shows that both AVP ϩ and AVP-negative but not OXT neurons were activated, suggesting that PYY induced satiation by stimulating AVP secretion. AVP is involved in appetite suppression by opposing neuropeptide Y (NPY)-induced orexigenic effects (Olson et al., 1991a,b; Verbalis et al., 1993; Aoyagi et al., 2009 ). Both intraperitoneal and OS PYY also induced p-ERK in a significant population within the parvocellular subnuclei of the PVN that are known to express CRF. CRF has been shown to act on the CNS to inhibit FI in several models of hyperphagia (Currie et al., 2001; Fekete et al., 2007) .
In the Arc, PYY activated ␣-MSH-expressing neurons known to reduce FI and increase energy expenditure (Fan et al., 1997) . It is worth noting that GLP-1R is colocalized with POMC (anorexigenic) but not with NPY (orexigenic) neurons within the Arc (Sandoval et al., 2008) . It is conceivable that the activation of the ␣-MSH-IR neurons we documented in fed and PYY-treated mice was mediated by the activation of GLP-1 neurons in the NST projecting into Arc. In this case, the increase of c-Fos-IR neurons in the LHA (Fig. 6 ) in PYY OS mice is probably relayed by direct Arc-to-LHA projections known to encode information related to taste hedonics and feeding (Nishijo et al., 2000) .
␣-MSH containing neurons in the Arc also activate downstream secondary neuronal populations at distant sites, such as the PBN, Amy, and NST (Belgardt and Brüning, 2010) . In the PBN, for example, melanocortin 4 receptor-IR neurons, activated by LiCl treatment, are located in lePBN nuclei known to be critical for the acquisition of CTA (Paues et al., 2006) .
Overall, these results strongly support the assumption that salivary PYY interferes directly or indirectly with neuronal networks dedicated to feeding and energy balance (Fig. 10) and that this could partially explain the OS PYY-induced hypophagia.
The PYY 3-36 -preferred receptor Y 2 R is expressed in the basal cell epithelia of the tongue (Acosta et al., 2011) , as well as in taste cells of the circumvallate papillae (Hurtado et al., 2012) . These PYY 3-36 -responsive cells could be candidates to transduce the information from salivary PYY . In fact, we have shown that the Y 2 R ϩ basal epithelial layer of the tongue responded robustly to PYY (Hurtado et al., 2012) . Therefore, although peripheral PYY 3-36 may exert its unique effects through the vagal nerve, salivary PYY 3-36 could affect the trigeminal, facial, and/or glossopharyngeal nerves, which carry afferent gustatory and somatosensory signals. At least one ascending GLPergic pathway links the NST to the Arc and PVN (Vrang et al., 2007; Llewellyn-Smith et al., 2011) , and there are descending Arc-NST, PVN-NST, and LHA-NST projections that are involved in appetite control (van der Kooy et al., 1984; Belgardt and Brüning, 2010; Blevins and Baskin, 2010) . Together, these data provide support for the existence of specific pathways connecting oral mucosa and hypothalamic brainstem circuits controlling ingestive behavior.
In summary, we have identified a novel putative alternative pathway that originates in sensory nerves of the oral cavity and projects, via the facial, glossopharyngeal, trigeminal nerves, and/or vagus branch to the NST in the brainstem (Fig. 10) . From the NST, the signal could be relayed to the Arc and PVN. The precise phenotype(s) of the neurons and connections involved remain to be identified. However, from the activation patterns of the NST, we can infer that PYY 3-36 could be inducing an anorectic effect through the regulation of the palatability of food. To the best of our knowledge, this is the first report demonstrating that PYY 3-36 administered into the oral cavity does not induce the adverse effect that is observed when PYY 3-36 is administered systemically. Degen et al. (2005) demonstrated that exogenously administered PYY 3-36 can suppress FI in humans only when used at the supraphysiological doses. Importantly, inhibition of feeding induced with such doses was accompanied by subjective dose-dependent side effects related to gastrointestinal malaise (associated with the CTA reported in animal models). As a result, the potential of PYY to emerge as a powerful antiobesity drug was challenged by its narrow therapeutic index. The discovery of an alternative pathway mediated by salivary PYY 3-36 and its receptors in the oral cavity that regulates ingestive behavior without inducing TA reveals the existence of a novel pathway for the NPY system that may serve as an important therapeutic target.
